3Russell EJ, Geremia GK, Johnson CE et al . Multiple cerebral metastases. Detectability with Gd - DTPA - enhanced MR imaging. Radiology, 1987,165(12) :609 - 617.
4Yuh WTC, Engelken JD, Muhonen MG et al . Kxperiences with highdose gadolinium MR imaging in the evalulation of brain metastases. AJNR Am J Neuroradiol, 1992,13( 1 ) :335 - 345.
5Luis MB, Teresa V, Carlos B et al . Safety and efficacy of omniscan(Gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age. Investigative Radiology,2000,35(2) : 141 - 147.
6Valk J, Algra PR, Hazenberg CJ et al . A double - blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology, 1993,35(3 ):173- 177.
7Imam K, Biuemke DA. MR imaging in the evaluation of hepatic metatases. Magn - Reson - Imaging- Clin- N- Am,2000,8:741 -756.
8Irie H, Honda H, Kaneko K et al . MR imaging of focal nodular hyperplasia of the liver: value of contrast - enhanced dynamic study. Radit -Med, 1997,15:29 - 35.
9Kieran PJM, FRCPC, Kazimierz TS et al . Occurrence of adverse reactions to gadolinium- based contrast material and management of patients at increased risk : a survey of the american society of neuroradiology fellowship directors. Acad Radiol, 1999,6:656 - 664.
二级参考文献4
1[1]Newhouse JH, Murphy RX Jr. Tissue distribution of soluble contrast: effect of dose variation and changes with time. AJR, 1981, 136: 463
2[2]Jerosch Heroid M, Wilke N. MR first pass imaging: quantitative assesament of transmittal perfusion and collateral flow. Int J card imaging, 1997, 13(3): 205
3[3]Small WC, Nelson RC, Bernardino ME et al. Contrast-enhanced spiral CT of the liver: effect of different amounts and injection rates of contrast material on early contrast enhancement. AJR, 1994, 163: 87
4[4]Yamashita Y, Hatanata Y, Yamamoto H, et al. Differential diagnosis of focal liver lesions: role of spin-echo and contrast enhanced dynarmc MR imaging. Radiology, 1994, 193: 59
4Grazioli L,Bondioni M P,Faccioli N.Solid focal liverlesions:dynamic and late enhancement patterns with thedual phase contrast agent gadobenate dimeglumine[J].Gastrointest Cancer,2010,41(4):221-232.
5Morana G,Grazioli L,Kirchin M A.Solid hypervascularliver lesions:accurate identification of true benign lesionson enhanced dynamic and hepatobiliary phase magneticresonance imaging after gadobenate dimeglumine adminis-tration[J].Invest Radiol,2011,46(4):225-239.
6Seale M K,Catalano O A,Saini S,et al.Hepatobiliary-specific MR contrast agents:role in imaging the liver andbiliary tree[J].Radiographics,2009,29(6):1725-1748.
7Hwang H S,Kim S H,Jeon T Y.Hypointense hepaticlesions depicted on gadobenate dimeglumine-enhancedthree-hour delayed hepatobiliary-phase MR imaging:differentiation between benignancy and malignancy[J].Korean J Radiol,2009,10(3):294-302.
8Schneider G,Altmeyer K,Kirchin M A,et al.Evaluationof a novel time-efficient protocol for gadobenate dimeglu-mine(Gd-BOPTA)-enhanced liver magnetic resonanceimaging[J].Invest Radiol,2007,42(2):105-115.
9Grazioli L,Morana G,Kirchin M A.Accurate differentia-tion of focal nodular hyperplasia from hepatic adenoma atgadobenate dimeglumine-enhanced MR imaging:pro-spective study[J].Radiology,2005,236(1):166-177.
10Brancatelli G,Federle M P,Grazioli L.Benign regener-ative nodules in Budd-Chiari syndrome and other vas-cular disorders of the liver:radiologic-pathologic andclinical correlation[J].Radiographics,2002,22(4):847-862.
